Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers: A Phase I Open-Label Study

By Lasseter K.C.  

Clinical Pharmacokinetics, Vol. 43, Iss. 2, 2004-01 ,pp. : 121-129

Adis International

Access to resources Recommend Favorite

The hepatic safety profile of duloxetine: a review

By McIntyre Roger S   Panjwani Zilomi D   Nguyen Ha T   Woldeyohannes Hanna O   Alsuwaidan Mohammad   Soczynska Joanna K   Lourenco Maria T   Konarski Jakub Z   Kennedy Sidney H  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 3, 2008-03 ,pp. : 281-285

Informa Healthcare

Access to resources Recommend Favorite

Profiles of Hepatic and Dysrhythmic Cardiovascular Events Following Use of Fluoroquinolone Antibacterials: Experience from Large Cohorts from the Drug Safety Research Unit Prescription-Event Monitoring Database

By Clark D.W.J.  

Drug Safety, Vol. 24, Iss. 15, 2001-01 ,pp. : 1143-1154

Adis International

Access to resources Recommend Favorite

The safety of rosuvastatin: effects on renal and hepatic function

By Guthrie Robert M   Martin Daniel R  

Expert Opinion on Drug Safety, Vol. 6, Iss. 5, 2007-09 ,pp. : 573-581

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin shows good hepatic/pancreatic safety profile

By  

Reactions Weekly, Vol. 1, Iss. 1278, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite